Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled vs Subcutaneous Insulin on Airway Lining Fluid in T2DM
NCT00143338Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2004
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of insulin human in type 2 diabetes mellitus (T2DM), sponsored by Pfizer. Primary endpoint: Lung lining fluid cell count and differential at 12 weeks. Started Nov 2004; status: completed.
02
Drugs
insulin human
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00143338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143338.